BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine


Original post, click here
This study is not yet open for participant recruitment.

See

Verified June 2017 by Allergan

Sponsor:

Information provided by (Responsible Party):

Allergan

ClinicalTrials.gov Identifier:

NCT03193346

First received: June 19, 2017

Last updated: June 19, 2017

Last verified: June 2017

This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.

Migraine Disorders Biological: botulinum toxin Type A Drug: placebo (sodium chloride 0.9 mg) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Primary Outcome Measures:

Secondary Outcome Measures:

  • Change from Baseline in the Frequency of Headache Days during 28-Day Period [ Time Frame: Baseline, Weeks 4, 8, 12, 16 and 20 ]

    Mean change from Baseline (28-days prior to first treatment) in frequency (number) of headache days during the 28-day period ending with Weeks 4, 8, 12, 16 and 20. A headache day was defined as a calendar day [00:00 to 23:59] for which the participant reported ≥ 4 continuous hours of headache per patient diary.

  • Change from Baseline in the Frequency of Migraine/Probable Migraine Days during 28-Day Period [ Time Frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24. ]

    Mean change from Baseline (28-days prior to first treatment) in frequency (number) of migraine or probable migraine episodes during the 28-day period ending with Weeks 4, 8, 12, 16, 20 and 24. A Migraine or Probable Migraine day was defined as a calendar day [00:00 to 23:59] for which the patient reported ≥ 4 continuous hours of a migraine or probable migraine episode as per the patient diary.

  • Change from Baseline in the Number of Moderate/Severe Headache Days during 28-Day Period [ Time Frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24 ]

    Mean change from Baseline (28-days prior to first treatment) in frequency (number) of headache days during the 28 day period ending with Weeks 4, 8, 12, 16, 20 and 24. A moderate/severe headache day is defined as a day (00:00 to 23:59) when a participant reported 4 or more continuous hours of headache and reported a maximum severity of moderate or severe per patient diary among all headache episodes that occurred on that day.

  • Change from Baseline in Total Cumulative Hours of Headache Days during 28-Day Period [ Time Frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24 ]

    Mean change from Baseline (28-days prior to first treatment) in the total cumulative hours of headache days during the 28-day period ending with Weeks 4, 8, 12, 16, 20 and 24. A headache day is defined as a day (00:00 to 23:59) with 4 or more continuous hours of headache per patient diary.

Estimated Enrollment: 700
Anticipated Study Start Date: July 3, 2017
Estimated Study Completion Date: March 25, 2021
Estimated Primary Completion Date: March 25, 2021 (Final data collection date for primary outcome measure)
Experimental: BOTOX®

BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.

Biological: botulinum toxin Type A

Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.

Other Names:

  • BOTOX®
  • onabotulinumtoxinA
Placebo Comparator: Placebo

Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.

Drug: placebo (sodium chloride 0.9 mg)

Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of chronic migraine prior to the baseline phase based on the revised criteria for chronic migraine listed in International Classification of Headache Disorders (ICHD)-3 beta (2013)
  • Fifteen or more headache days during the 4-week baseline phase, with each day consisting of 4 or more hours of continuous headache
  • Routine non-headache medications of stable dose and regimen for at least 1 month prior to the start of screening.

Exclusion Criteria:

  • Participants diagnosed with any of the following headache disorders: Familial hemiplegic migraine, Sporadic hemiplegic migraine, Migraine with brainstem aura, Migrainous infarction, Chronic tension-type headache, Hypnic headache, Hemicrania continua, New daily-persistent headache and Recurrent painful ophthalmoplegic neuropathy
  • Participants with a confirmed history of medication overuse headache
  • Participants with a diagnosis of retinal migraine, persistent aura without infarction or migraine-triggered seizure
  • Headache attributable to another disorder (eg, cervical dystonia, craniotomy, head/neck trauma)
  • Use of any headache prophylactic medication within 28 days prior to the start of the screening
  • Any medical condition that may put the patient at increased risk with exposure to Botulinum Toxin Type A, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
  • Participants with a known or suspected Temporomandibular Disorder (TMD), including pain in or around the Temporomandibular Joint (TMJ)
  • Participants with a concurrent diagnosis of fibromyalgia
  • Previous treatment with botulinum toxin therapy for any reason, or immunization to any botulinum toxin serotype
  • Acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction, nociceptive trigeminal inhibition or occipital nerve block treatments, or injection of anesthetics or steroids into the study target muscles within 28 days prior to the start of the screening
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03193346

Allergan

Study Director: Arlene Lum Allergan

Additional Information:

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT03193346     History of Changes
Other Study ID Numbers: 1313-301-008
Study First Received: June 19, 2017
Last Updated: June 19, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms
onabotulinumtoxinA
Botulinum Toxins, Type A
abobotulinumtoxinA
incobotulinumtoxinA
Botulinum Toxins
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on June 20, 2017